Yazar "Eygi, B." seçeneğine göre listele

Listeleniyor 1 - 2 / 2
  • Küçük Resim Yok
    Öğe
    Sol ana koroner arterin total oklüzyonunda miyokard koruması ve cerrahi tedavi
    (2012) Oğuz, E.; Engin, Ç; Ayık, F.; Durmaz, I.; Eygi, B.
    Sol ana koronerin total oklüzyonu nadir görülen bir patolojidir. Özellikle akut oklüzyonlar ölümcül seyrettiğinden bu konu ile ilgili çok az sayıda yayın bulunmaktadır. Bu makalede elektif olarak yapılan anjiyo sırasında tespit edilmiş sol ana koroner arteri total oklüde olan bir olgunun başarılı cerrahi tedavisi ve cerrahi sırasında miyokardiyal koruma için yapılan teknikler anlatılmıştır.
  • Küçük Resim Yok
    Öğe
    Ventricular Assist Device as a Bridge to Heart Transplantation in Adults
    (Elsevier Science Inc, 2011) Engin, C.; Ayik, F.; Oguz, E.; Eygi, B.; Yagdi, T.; Karakula, S.; Ozbaran, M.
    Background. Because of the shortage of donor hearts, various ventricular asist devices (VAD) have been used in decompensated patients to prolong patient survival until a suitable heart becomes available. In this paper, we present our single-center report of adult patients in whom bridging was used with VAD. Methods. We performed a retrospective review of 14 adult patients who underwent heart transplantation after insertion of a long-term VAD. The study spans from February 2006 until September 2010. The mean patient age was 44.28 +/- 11.06 years. We used the Berlin Heart EXCOR VADs (n = 11; Berlin Heart AG Berlin, Germany), or the Berlin Heart Incor (n = 2), or the Abiomed AB500 (n = 1). Preimplantation status of the subjects were critical cardiogenic shock (n = 6), deterioration on inotropes (n = 3), or stable but inotrope-dependent (n = 5). Results. Mean VAD support time was 153.71 days (range, 25-517). Major adverse events during VAD support included reexploration for bleeding (n = 3; 21.4%), neurologic events (n = 2; 14.3%), left VAD-related infection (n = 2; 14.3%), pneumonia (n = 1; 14.3%), or primary device failure (n = 1; 7.1%). One (7.1%) patient showed evidence of human leukocyte antigen sensitization. There were 2 deaths (14.3%) over a mean of 324 days follow-up after heart transplantation: One due to biventricular failure in the early postoperative period and the other, at 69 days from pneumonia. Rejection was observed in 2 patients who had International Society for Heart and Lung Transplantation grade 2R without hemodynamic deterioration. In our series, the 1-year mortality was 14.4% among heart transplantations without VAD implantation and 14.2% among the bridge-to-transplantation group. Conclusion. We conclude that VAD implantation improved end-organ function before heart transplantation in critically ill patients.